VTX-2735 is under clinical development by Ventyx Biosciences and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VTX-2735’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VTX-2735 is under development for the treatment of systemic inflammatory diseases, cryopyrin-associated periodic syndrome (CAPS) including familial cold autoinflammatory syndrome (familial cold urticaria). It is administered by oral route and acts by targeting NACHT, LRR and PYD domains-containing protein 3 (NLRP3).
Ventyx Biosciences overview
Ventyx Biosciences is a clinical-stage biotechnology company that discover and develops novel drugs for inflammatory diseases and autoimmune disorders. The company’s pipeline include VTX958, a TYK2 inhibitor for the treatment of various autoimmune diseases; VTX002, S1P1 receptor modulator for the treatment of ulcerative colitis and others. Ventyx Biosciences headquartered in Encinitas, California, the US.
For a complete picture of VTX-2735’s drug-specific PTSR and LoA scores, buy the report here.